74904-29-3

Usage

Uses

Used in Pharmaceutical Industry:
3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one is used as a therapeutic agent for the treatment of schizophrenia, Alzheimer's disease, and other cognitive disorders. It targets the muscarinic acetylcholine receptor subtype M1, which is implicated in cognitive functions, and may help improve symptoms associated with these conditions.
Used in Drug Addiction Treatment:
3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one is used as a potential treatment for drug addiction. Its antagonistic action on the muscarinic acetylcholine receptor subtype M1 may help in reducing cravings and relapse rates in individuals struggling with addiction.
Used in Neurological Disorder Research:
3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one is used as a research tool in the investigation of various neurological disorders. Its selective antagonism of the M1 receptor subtype provides insights into the role of this receptor in the pathophysiology of these conditions and may lead to the development of new therapeutic strategies.

Upstream product

• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 108-95-2 phenol 
• 6968-35-0 7-hydroxy-indan-1-one 
• 24552-27-0 3-chloropropionic acid phenyl ester 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 5411-61-0 4-bromo-7-methoxy-2,3-dihydro-1H-inden-1-one 
• 66192-02-7 3-(2-bromo-5-methoxyphenyl)propanoic acid 
• 81625-30-1 2-(ethoxycarbonyl)-3-methoxybenzyl chloride 
• 81625-29-8 N,N-dimethyl-2-(ethoxycarbonyl)-3-methoxybenzylamine 
• 81625-31-2 2-(ethoxycarbonyl)-3-methoxyphenylacetonitrile 
• 15184-99-3 N,N-dimethyl-3-methoxybenzylamine 
• 163713-49-3 3-(3-Methoxy-phenyl)-propionyl azide 
• 40478-49-7 3-(3-methoxyphenyl)propanoyl chloride 

Downstream Products

• 34146-68-4 8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-33-4 N-(benzenesulfonyl)-3,4-dihydro-3-methoxyisocarbostyril 
• 464900-21-8 8-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 32999-37-4 1,2,3,4-tetrahydroisoquinoline-8-ol 
• 1723-70-2 8-methoxyisoquinoline 
• 81625-36-7 2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-35-6 1-hydroxy-2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-39-0 2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-37-8 2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-40-3 1-<4-(benzyloxy)benzyl>-2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-41-4 1-<4-(benzyloxy)benzyl>-2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-20-9 1-(3,4-dimethoxybenzyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-22-1 1-<4-(benzyloxy)benzyl>-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 73903-30-7 8-Methoxy-2-methyl-1,2,3,4-tetrahydroisochinolin 

Relevant academic research and scientific papers

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

TREATING LONG QT SYNDROME

This document relates to compounds useful for treating and preventing disorders associated with long QT syndrome such as cardiac arrhythmia, ventricular arrhythmia, hypertrophic cardiomyopathy, and congestive heart failure. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.

Facile synthesis of 5-To 7-membered benzolactam compounds via strongly facilitated electrophilic aromtic substitution reaction

We employed our system to activate aromatic ring-Tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5-To 7-membered rings, and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction, and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction, but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality.

Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their density. With the aim of contributing to the research of σ2 receptor Positron Emission Tomography (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3, 4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacological properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiography on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression.

Synthesis and SAR of novel histamine H3 receptor antagonists

The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H3 receptors are reported.

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof. Also disclosed is the treatment of chemokine-mediated diseases using compounds of the formula (II)